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Abstract
Homologous recombination (HR) is the major pathway for repairing double strand breaks (DSBs) in eukaryotes and
XRCC2 is an essential component of the HR repair machinery. To evaluate the potential role of mutations in gene re-
pair by HR in individuals susceptible to differentiated thyroid carcinoma (DTC) we used high resolution melting
(HRM) analysis, a recently introduced method for detecting mutations, to examine the entire XRCC2 coding region in
an Iranian population. HRM analysis was used to screen for mutations in three XRCC2 coding regions in 50 patients
and 50 controls. There was no variation in the HRM curves obtained from the analysis of exons 1 and 2 in the case
and control groups. In exon 3, an Arg
188His polymorphism (rs3218536) was detected as a new melting curve group
(OR: 1.46; 95%CI: 0.432-4.969; p = 0.38) compared with the normal melting curve. We also found a new Ser
150Arg
polymorphism in exon 3 of the control group. These findings suggest that genetic variations in the XRCC2 coding re-
gion have no potential effects on susceptibility to DTC. However, further studies with larger populations are required
to confirm this conclusion.
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Introduction
Thyroid canceristhemostcommonendocrinemalig-
nancy and its incidence has increased in recent years
(Leenhardt et al., 2004; Davies and Welch, 2006; Jemal et
al., 2008). Differentiated thyroid carcinoma (DTC) is the
most common type of all thyroid carcinomas (accounting
for ~90% of all cases) and consists of papillary, follicular
and Hürthle cell carcinomas, the latter being a subtype of
follicular thyroid carcinoma (Hundahl et al., 1998). Risk
factors associated with DTC include exposure to various
carcinogenic agents, ethnicity and dietary habits, although
exposure to ionizing radiation is still the only recognized
risk factor (Ron et al., 1995; Xiong et al., 2005; Preston et
al., 2007).
Recentstudieshaveproposedthatgeneticvariationin
conserved DNA repair systems may influence susceptibil-
ity to cancer (Gatzidou et al., 2010). These systems nor-
mally ensure the genetic intactness of cell populations such
that any alteration in the genes related to these systems
could lead to a defect in DNA repair pathways and ulti-
matelyaffectthecellulargeneticstabilityandsusceptibility
to cancer. In severe DNA damage, such as double-strand
breaks (DSBs), there are two important recombination sys-
tems for cell survival, namely, homologous recombination
(HR) and non-homologous end joining (NHEJ) (Paques
and Haber, 1999; Peterson and Cote, 2004).
In eukaryotes, HR is the major pathway for DSB re-
pair and has an important role in preventing mutations,
chromosomal instability and cancer; these functions make
HR essential for cell viability and genomic stability (Jack-
son, 2002; Thompson and Schild, 2002). The HR repair
system functions primarily during the S and G2 phases of
thecellcycle.SinceHRisanerror-freepathwayofdamage
tolerance that allows the replication bypass of lesions dur-
ing a template switch it has a distinct advantage over NHEJ
(Jackson, 2002; Thompson and Schild, 2002).
The RAD51 gene family is the key component of HR
anditsimpairmentcanleadtoextremesensitivitytocertain
DNA damaging agents, intense genomic instability and a
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Research Articlerisk of cancer (Sonoda et al., 1998; Cui et al., 1999; Deans
et al., 2000, 2003; Takata et al., 2001; Gruver et al., 2005;
Siraj et al., 2008). The RAD51-like gene family in somatic
mammalian cells is composed of XRCC2, XRCC3,
RAD51L1, RAD51L2 and RAD51L3 (Thacker, 1999).
There are indications that XRCC2 has an important role in
enhancing the action of RAD51, with a loss of XRCC2 de-
laying the early steps of HR, including the integration of
RAD51 at the site of DNA damage, nucleoprotein filament
formationandstrandinvasion(Sugawaraetal.,2003;Wol-
ner et al., 2003). In XRCC2-deficient cells, RAD51 re-
sponses are reduced by approximately five-fold, and this
has led to XRCC2 being recognized as a repair response-
enhancing factor (Tambini et al., 2010).
XRCC2isa29,668kbgenelocatedonhumanchromo-
some 7q36.1 and consists of three exons (1 to 3) that contain
38, 82 and 722 bp, respectively. XRCC2 protein is highly
conserved among mammalian species (Tambini et al.,
2010). Several studies have examined the association be-
tween genetic polymorphisms in XRCC2 and different can-
cers (Han et al., 2004; Jiao et al., 2008; Curtin et al., 2009).
In the present report, we describe the first case-control study
of an Iranian population to examine the association between
mutationsintheentirecodingregionoftheXRCC2geneand
individual susceptibility to DTC based on high resolution
melting (HRM) analysis, a recently introduced method for
detecting mutations (Montgomery et al., 2010).
Materials and Methods
Study subjects
A sample size calculation (Kasiulevicious et al.,
2006) indicated that the minimum sample size for this
case-control study was ~45 for each group (controls and
cases).Inaddition,theminimumoddsratio(OR)forsignif-
icance was 2.5 (p < 0.05). The probability of having a mu-
tant allele in the XRCC2 coding region in control individu-
als was estimated as 0.35. Based on these preliminary
calculations, our study population consisted of 50 patients
with histopathologically confirmed DTC and 50 controls.
Informed consent was obtained from all participants before
commencementofthestudyandthestudywasapprovedby
the ethics committee of Tehran University of Medical Sci-
ence. The DTC patients were recruited from the Research
InstituteforNuclearMedicineofShariatiHospital,Tehran,
Iran. The control population was matched for age ( 50 and
> 50 year) and sex, with no previous or concurrent malig-
nantdisease.Thecontrolswererecruitedfromvolunteersat
two academic centers in Tehran. Individuals with a history
of other cancers, radiation exposure, alcohol consumption
or smoking were excluded from the study.
DNA extraction
5 mL of peripheral blood was collected from each
subject into tubes containing 1 mL of EDTA (1 g/dL) and
stored at -20 °C until used. Whole blood DNA was ex-
tracted by a salting out procedure (Miller et al., 1988).
Primer design and assay conditions for PCR-HRM
One primer pair for exon 1 (Ex1), three primer pairs
for exon 2 (Ex2) and three primer pairs for exon 3 (Ex3)
were used in this work (Table 1). PCR-HRM was done in a
Rotor-Gene 6000 real-time rotary analyzer (Corbett Life
Sciences). The reactions were prepared in 10 L volumes
in 0.1 mL strip tubes of a 72-well rotor. For symmetric
PCR-HRM, the amount of DNA in each reaction was ad-
justed to 50 ng. Each reaction contained 5 Lo f2xH R M
PCR Master Mix (Type-it HRM PCR kit, QIAGEN),
0.7 L (10 M) of primer mix, 1.5 L (50 ng) of DNA and
DNA RNase-free water to a final volume of 10 L.
The PCR cycling profile is summarized in Table 1.
After amplification, HRM analysis data were collected
from 65 °C to 85 °C, with each step raised by 0.05 °C, fol-
lowedbyawaitingtimeof10s.Samplesfromthetop,mid-
dle and bottom of each melting curve group and suspicious
melting curves were sequenced. Any new mutation de-
tected by PCR-HRM was screened for in the other samples
by using the Allele Refractory Mutation System (ARMS).
The ARMS primers and fragment lengths are listed in Ta-
ble 1.
Statistical analysis
Hardy-Weinberg equilibrium of the XRCC2 alleles in
the control population was assessed using the Chi square
test (
2). The homogeneity of age distribution between the
controls and cases was assessed with an independent sam-
ple t-test and Levene’s test. Allelic and genotypic frequen-
cieswerecomparedacrossgroupsusingtheChisquaretest.
Theoddsratio(OR)andthecorresponding95%confidence
intervals (CIs) between DTC and a detected polymorphism
werecalculatedusinglogisticregression.Allanalyseswere
done with SPSS v13 software.
Results
This study included 50 DTC patients and 50 can-
cer-freecontrols.Thetwogroupswerematchedforsexand
age ( 50 and > 50 years). The mean age ( SEM) in the
cases and controls was 38.4  2.1 and 36.2  1.2 years, re-
spectively. Age and sex were not significantly different be-
tween the two groups. The general characteristics of both
groups are shown in Table 2.
HRM analysis results
HRManalysisshowednovariationsinthemeltphase
analysis curves for the Ex1, Ex2a, Ex2b, Ex2c, Ex3a and
Ex3cfragmentsinthecaseandcontrolgroups.Anewmelt-
ing curve group was detected in the Ex3b fragment com-
pared to the normal melting curves retrieved from the wild
typegenotypegroup(Figure1).Toconfirmtheexistenceof
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ment, the samples in this group were subjected to DNA se-
quencing and a previously reported polymorphism
(Arg
188His, rs3218536) was detected in all of them. No
His/His alleles were found in the population. Table 2 sum-
marizes the distributions of the allelic and genotypic
frequencies in the case and control groups.
Another suspicious melting curve was identified in
theEx3bfragmentandDNAsequencingconfirmedanovel
missense mutation (AGC  AGG, Ser
150Arg) in one sam-
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Table 1 - (A) Primers for the XRCC2 coding regions and the PCR conditions used before HRM analysis. (B) Primers used in PCR-ARMS.
Exon number Primer (5’ to 3’) Amplicon size (bp) PCR conditions
A
Exon1 (Ex1) F: TATTGCGCATGCTCCCGCC
R: CCAATCCCCCGGGTTCCC
277 95 °C, 5 min; 45 cycles (95 °C, 10 s; 64 °C, 30 s; 72 °C,
16 s); 72 °C, 5 min
Exon2a (Ex2a) F: GGTATAAATATAGATGTCTAGG
R: GGTTCTATTTCTTTCAG
118 95 °C, 5 min; 45 cycles (95 °C, 10 s; 52 °C, 30 s; 72 °C,
16 s); 72 °C, 5 min
Exon2b (Ex2b) F: CCTTCTCTCTTCTTTTATAAGC
R: ACAGGTGAATCTTCATCAGC
99 95 °C, 5 min; 45 cycles (95 °C, 10 s; 57 °C, 30 s; 72 °C,
16 s); 72 °C, 5 min
Exon2c (Ex2c) F: GACTTGAAGGTAGAAGTTCC
R: CTTGTGAGGAGTATGTGTATAC
164 95 °C, 5 min; 45 cycles (95 °C, 10 s; 56 °C, 30 s; 72 °C,
16 s); 72 °C, 5 min
Exon3a (Ex3a) F: CTTTCACATTCCAGTAAGTGTC
R: GTAAAGTGTAAGAAGTAAGTGGG
379 95 °C, 5 min; 45 cycles (95 °C, 10 s; 57 °C, 30 s; 72 °C,
16 s); 72 °C, 5 min
Exon3b (Ex3b) F: TCAAATACTGCCTGGGAAG
R: CTGCCATGCCTTACAGAG
373 95 °C, 5 min; 45 cycles (95 °C, 10 s; 57 °C, 30 s; 72 °C,
16 s); 72 °C, 5 min
Exon3c (Ex3c) F: CAAACTATAATGCAGAAAGCC
R: GAGCCATGATTGTGCCAC
376 95 °C, 5 min; 45 cycles (95 °C, 10 s; 64 °C, 30 s; 72 °C,
16 s); 72 °C, 5 min
B
Exon3b (Ex3b)-F TCAAATACTGCCTGGGAAG
Exon3b (Ex3b)-R CTGCCATGCCTTACAGAG 273, 265
ARMs C (wild) CCTTTTGATTTTGGATAGC 95 °C, 2 min; 30 cycles (95 °C, 10 s; 58 °C, 30 s; 72 °C,
16 s); 72 °C, 4 min Exon3b (Ex3b)-F TCAAATACTGCCTGGGAAG
Exon3b (Ex3b)-R CTGCCATGCCTTACAGAG 273, 147
ARMs G (mutant) TCCAGTAAAAAGCTGACAGC
F- forward, R- reverse.
Figure 1 - (A) HRM curves for exon 3b (Ex3b) of the XRCC2 gene in patients and controls. The Arg
188His genotype (red curves) was detected as a new
melting curve group in a few patients and controls compared with the normal melting curves obtained for the wild type (Arg
188) genotype (blue curves).
(B) Difference graph of the HRM curves.ple of the control group. No mutation was detected in the
other samples screened for this mutation using ARMS.
The difference between the Arg
188His and Arg
188
genotypic frequencies was not significant and there was no
significant association between DTC and the G and A
allelic frequencies (Table 2).
Discussion
In this study, we used HRM analysis to screen for ge-
netic mutations in the entire coding region of the XRCC2
gene and examined the association between these muta-
tions and DTC in a subpopulation from Tehran, Iran. HRM
analysis is an innovative technique for genotyping that is
based on DNA melting analysis such that any alteration in
genotype leads to variation in the HRM curves when com-
pared to the wild type (Montgomery et al., 2010). To our
knowledge, this is the first time that the entire coding re-
gion of the XRCC2 gene has been analyzed. Two
polymorphisms, CGC  CAC (Arg
188His, rs3218536) and
AGC  AGG (Ser
150Arg), were identified in Ex3b of the
XRCC2 gene. To detect the Arg
188His polymorphism we
distinguishedbetweenwildhomozygote(G::C)andhetero-
zygote(A::T,G::C)samplesbasedonadiscerniblemelting
transition (Figure 1A).
There was no significant association between DTC
and the Arg
188His polymorphism and its genotypic fre-
quency in the individuals studied (Table 2). Bastos et al.
(2009) and Garcia-Quispes et al. (2011) also found no sig-
nificant involvement of the XRCC2 Arg
188His polymor-
phism in thyroid cancer in 109 (OR: 0.8, 95%CI: 0.4-1.6)
and 402 (OR: 1.12, 95%CI: 0.80-1.59) patients, respec-
tively. There are currently no additional data on the rela-
tionship between the XRCC2 Arg
188His polymorphism and
thyroid cancer.
A recent meta-analysis by Yu et al. (2010) reported
that there was no evidence of a significant association be-
tweenXRCC2Arg
188Hisandtheriskofbreastcancerinany
genetic model. A meta-analysis of three case-control stud-
ies in the United Kingdom and a family-based study in the
United States found no association between a putatively
functional Arg
188His SNP and colorectal cancer (Curtin et
al., 2009). Similarly, a meta-analysis of 16 studies com-
piledbytheInternationalOvarianCancerAssociationCon-
sortium showed there was also no association between
Arg
188His and the risk of ovarian cancer (Pearce et al.,
2009).However,theXRCC2Arg
188Hispolymorphismmay
beageneticmodifierforsmoking-relatedpancreaticcancer
(Jiao et al., 2008).
Alignment of the protein sequence of human XRCC2
withthatofotherspeciesrevealedanArg
188Hissubstitution
in Gallus gallus and Pongo abelii (Figure 2). Furthermore,
Arg
188 is not present at the active site of three XRCC2 pro-
teins. This finding suggests that the Arg
188His polymor-
phism generated in homologous recombination repair
pathway may not have severe effects on XRCC2 function
and may not influence the susceptibility to cancer in hu-
mans.
We detected a novel missense mutation (AGC 
AGG, Ser
150Arg) in the XRCC2 gene in one sample of the
control group. In this G::C conversion, bases switched
strands but the GC content was conserved and the melting
transitions of heterozygote, wild and variant homozygotes
Fayaz et al. 35
Table 2 - General characteristics of the case and control groups and the
allelic and genotypic (Arg
188His) frequencies of XRCC2.
Variable Case n (%) Control n (%) p OR (95% CI)
Age (years)
 50 44 (88%) 44 (88%) 0.383
> 50 6 (12%) 6 (12%)
Sex
Male 12 (24%) 12 (24%) 1.000
Female 38 (76%) 38 (76%)
Genotype (Arg
188His)
GG 43 (86%) 45 (90%) 0.38ª 1.46
GA 7 (14%) 5 (10%) (0.432-4.969)
b
Allele frequency
G 93 (0.93%) 95 (0.95%) 0.39ª 1.43
A 7 (0.07%) 5 (0.05%) (0.438-4.666)
c
ªOne tailed chi-squared analysis comparing genotype distributions and
allelic frequencies between cases and controls.
bOR (95%CI) GA to GG genotype (Arg
188His) of XRCC2 for case vs. con-
trol groups.
cOR (95%CI) A to G allele (Arg
188His) of XRCC2 for case vs. control
groups.
Figure 2 - Multiple protein sequence alignment of a selected region of Homo sapiens XRCC2 with that of other species. Highlighted amino acids repre-
sent Ser
150 and Arg
188 of H. sapiens XRCC2 compared with other species.were not clearly distinguishable (Cai et al., 2010). We
thereforeusedPCR-ARMStodetectthisSNPinothersam-
ples. Ser
150, which is involved in the formation of the ATP
binding site in XRCC2, is highly conserved among species
(Figure 2). Consequently, an Arg substitution at this posi-
tion (replacing a neutral amino acid by a positively charged
one) would most probably affect the formation of the ATP
binding site. However, protein expression studies are
needed to confirm this hypothesis.
The major limitation of this study is the sample size,
whichmaybeduetolesserprobabilityofdetectinganyrare
mutationsinsmallersamplesize.Ontheotherhand,forde-
tected SNP, the larger sample size would make the results
more significant. In this regard, the coexistence of other
members of the Rad51 gene family with an impaired func-
tion alongside Arg
188His should be considered since these
proteins are also involved in the HR repair system. For ex-
ample, Bastos et al. (2009) showed that the coexistence of
three or more variant alleles in the RAD51 and XRCC3
genes was associated with a significantly higher risk of
DTC (OR = 2.9, p = 0.036; four variant alleles: adjusted
OR = 8.0, p = 0.006), while no associations were observed
for polymorphisms in XRCC3 alone (Bastos et al., 2009;
Garcia-Quispes et al., 2011).
Inconclusion,ourfindingsindicatethatthereisnoas-
sociationbetweenpolymorphismsintheXRCC2codingre-
gion and the risk of DTC. However, further studies with a
larger population are needed to confirm this conclusion. In
addition, it would be prudent for other members of the
Rad51 gene family also to be screened for SNPs in their
coding region. Finally, HRM analysis was found to be very
usefulforgenotyping,althoughitwasunabletodistinguish
between G::C and A::T conversions because of the low
melting curve transition. Other complementary methods
are needed to overcome this limitation.
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